Personalis announced that Medicare will cover its NeXT Personal molecular residual disease (MRD) test for surveillance of patients with Stage I‑III non‑small cell lung cancer (NSCLC). The decision, made on February 10 2026, follows clinical evidence from the TRACERx consortium that demonstrates the test’s ability to detect residual disease with high sensitivity using whole‑genome sequencing and advanced noise‑suppression technology.
The coverage is a significant regulatory milestone because it opens a large payer market for a highly sensitive diagnostic that can identify circulating tumor DNA (ctDNA) at levels as low as one mutation per 10 million cells. The TRACERx data, which tracks up to 1,800 mutations, underpins the test’s clinical validity and positions Personalis ahead of competitors that rely on less sensitive assays.
From a business perspective, Medicare coverage broadens patient access to the test and provides a new revenue stream that supports the company’s transition to a clinical diagnostics model. The coverage is expected to accelerate the adoption of the test in the U.S. market, where Medicare represents a substantial portion of the oncology payer base. Management has indicated that the coverage will help the company move from a service‑based model to a product‑centric model, potentially improving margin profiles and scalability.
Investors reacted positively to the announcement, with analysts noting the coverage as a catalyst for growth. The decision is seen as a validation of the company’s technology platform and a key step toward expanding its diagnostics portfolio beyond breast cancer, where Medicare coverage was previously secured.
CEO Chris Hall emphasized that the coverage “broadens patient access to NeXT Personal for one of the most common cancers in the U.S. and is a catalyst for our continuing growth.” Chief Medical Officer Dr. Richard Chen added that the coverage “helps cancer patients and physicians navigate uncertainty in their cancer journey.”
The Medicare approval positions Personalis to capture a growing demand for precision oncology diagnostics, strengthens its competitive advantage, and supports the company’s long‑term strategy to become a leading provider of MRD testing across multiple cancer types.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.